Hunter Associates Investment Management LLC Has $228,000 Stake in Veeva Systems Inc. (NYSE:VEEV)

Hunter Associates Investment Management LLC grew its holdings in Veeva Systems Inc. (NYSE:VEEV) by 8.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,163 shares of the technology company’s stock after purchasing an additional 90 shares during the period. Hunter Associates Investment Management LLC’s holdings in Veeva Systems were worth $228,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in VEEV. MetLife Investment Management LLC acquired a new position in shares of Veeva Systems in the 1st quarter valued at about $1,906,000. Dimensional Fund Advisors LP grew its stake in shares of Veeva Systems by 1.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 190,289 shares of the technology company’s stock valued at $40,430,000 after buying an additional 3,286 shares in the last quarter. Sequoia Financial Advisors LLC grew its stake in shares of Veeva Systems by 11.5% in the 1st quarter. Sequoia Financial Advisors LLC now owns 1,018 shares of the technology company’s stock valued at $216,000 after buying an additional 105 shares in the last quarter. National Pension Service grew its stake in shares of Veeva Systems by 3.0% in the 1st quarter. National Pension Service now owns 195,170 shares of the technology company’s stock valued at $41,466,000 after buying an additional 5,607 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Veeva Systems by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 12,888,204 shares of the technology company’s stock valued at $2,738,229,000 after buying an additional 132,560 shares in the last quarter. Institutional investors and hedge funds own 88.20% of the company’s stock.

Analyst Ratings Changes

VEEV has been the subject of several recent research reports. Needham & Company LLC reissued a “buy” rating and issued a $260.00 price target on shares of Veeva Systems in a research note on Tuesday, April 2nd. Oppenheimer reissued an “outperform” rating and issued a $225.00 price target on shares of Veeva Systems in a research note on Thursday, February 22nd. Citigroup boosted their price target on Veeva Systems from $240.00 to $264.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Royal Bank of Canada reaffirmed an “outperform” rating and set a $250.00 target price on shares of Veeva Systems in a research report on Wednesday, March 27th. Finally, Piper Sandler upped their target price on Veeva Systems from $220.00 to $245.00 and gave the stock an “overweight” rating in a research report on Friday, March 1st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, Veeva Systems presently has a consensus rating of “Moderate Buy” and an average target price of $234.90.

Insider Activity at Veeva Systems

In other Veeva Systems news, SVP Jonathan Faddis sold 3,598 shares of the stock in a transaction on Monday, April 15th. The stock was sold at an average price of $207.42, for a total transaction of $746,297.16. Following the completion of the transaction, the senior vice president now directly owns 10,668 shares in the company, valued at $2,212,756.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Veeva Systems news, SVP Jonathan Faddis sold 3,598 shares of the stock in a transaction on Monday, April 15th. The stock was sold at an average price of $207.42, for a total transaction of $746,297.16. Following the completion of the transaction, the senior vice president now directly owns 10,668 shares in the company, valued at $2,212,756.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Timothy S. Cabral sold 15,000 shares of the stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $226.04, for a total value of $3,390,600.00. Following the transaction, the director now owns 23,391 shares of the company’s stock, valued at $5,287,301.64. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 19,836 shares of company stock worth $4,396,902. 10.98% of the stock is owned by corporate insiders.

Veeva Systems Price Performance

Shares of NYSE VEEV traded down $1.16 during trading hours on Friday, reaching $198.38. The stock had a trading volume of 735,422 shares, compared to its average volume of 955,618. The business’s fifty day moving average is $221.17 and its two-hundred day moving average is $202.80. The company has a market cap of $32.00 billion, a price-to-earnings ratio of 61.61, a PEG ratio of 2.02 and a beta of 0.74. Veeva Systems Inc. has a twelve month low of $160.21 and a twelve month high of $236.90.

Veeva Systems (NYSE:VEEV) last issued its earnings results on Thursday, February 29th. The technology company reported $0.92 EPS for the quarter, beating analysts’ consensus estimates of $0.81 by $0.11. The business had revenue of $630.62 million during the quarter, compared to analyst estimates of $620.75 million. Veeva Systems had a return on equity of 11.26% and a net margin of 22.24%. Sell-side analysts forecast that Veeva Systems Inc. will post 4.11 earnings per share for the current fiscal year.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.